Details

Autor(en) / Beteiligte

• Abboud, Steven F.
• Rastinehad, Ardeshir
• George, Arvin Koruthu
• Frye, Thomas P
• Ho, Richard
• Shakir, Nabeel Ahmad
• Chelluri, Raju
• Fascelli, Michele
• Walton-Diaz, Annerleim
• Sankineni, Sandeep
• Turkbey, Baris
• Choyke, Peter L.
• Merino, Maria J
• Pinto, Peter A.

Titel

External validation of multiparametric MRI and fusion-guided prostate biopsy: A matched cohort analysis

Ist Teil von

• Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.155-155

Erscheinungsjahr

2015

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract only 155 Background: MRI/US fusion-guided biopsy has been shown to improve the detection of clinically significant prostate cancer (PCa). As adoption of this novel technology expands, the reproducibility of outcomes from expert centers becomes essential. The objective of our study was to validate the comprehensive NCI experience of multiparametric MRI and fusion-guided biopsy (FB) with an external, independent, matched cohort of patients. Methods: We compared 1,003 patients enrolled from August 2007 through February 2014 in a prospective trial comparing systematic 12-core biopsy (SB) to FB at the NCI to 256 patients that underwent an identical procedure at Long Island-Jewish Hospital (LIJH) from February 2012 to June 2014. Patients from LIJH were matched 1:1 for age, PSA, and MRI suspicion score to a corresponding cohort of NCI patients. Clinically-significant (CS) disease was defined as a Gleason score of ≥4+3 in any biopsy core. Results: The overall cancer detection rate was 564/1,003 (56%) of NCI patients and 167/256 (65%) of LIJH patients. In the matched cohort analysis, cancer detection rate (CDR) by FB between cohorts was 52% NCI vs. 54% LIJH (p=0.67). Both cohorts demonstrated a similar rates of upgrading by FB compared to SB, 29% NCI vs. 23% LIJH (p=0.42). This trend applied to patients that upgraded to CS disease by FB, 12.7% NCI vs. 12.6% LIJH (p=0.42) (Table). Conclusions: The improved detection of clinically-significant cancer by mpMRI and FB is reproducible in the hands of an experienced multi-disciplinary team. Our results suggest that with appropriate training in the interpretation of mpMRI and performance of FB, dissemination of this technology can render equivalent outcomes. [Table: see text]